Skip to main content
Clinical Trials/NCT04869293
NCT04869293RecruitingNot Applicable

Assessment of Analgesia Through Hypnosis With 3D Virtual Reality During Extra-corporeal Lithotripsy (LAHMA)

Assistance Publique - Hôpitaux de Paris3 sites in 1 country106 target enrollmentStarted: April 15, 2021Last updated:
Conditions

Trial Snapshot

Phase
Not Applicable
Status
Recruiting
Enrollment
106
Locations
3
Primary Endpoint
Remifentanil use

Study Overview

Brief Summary

The study is a randomised trial of hypnosis with 3D virtual reality headset (intervention group) versus control group with no hypnosis and no virtual reality headset to compare remifentanil consumption during shock wave lithotripsy.

Detailed Description

The study is for patients undergoing shock wave lithotripsy in outpatient surgery unit.

It is proposed that using hypnosis with 3D virtual reality headset will reduce the requirements for intravenous remifentanil in a randomised controlled trial of one hundred and six patients.

Remifentanil is an opioid commonly used for lithotripsy. Shock wave lithotripsy is a commonly performed procedure associated with moderate pain and anxiety, in outpatient surgery unit. Opioids can cause unfavourable side-effects, most notably respiratory depression, sedation, nausea and vomiting

It is expected that by using 3D virtual reality to reduce pain and anxiety, there will be a reduced requirement for intravenous remifentanil.

The study will measure the dose of remifentanil required by patients randomised to receive either hypnosis with 3D virtual reality headset (intervention) or no hypnosis and no 3D virtual reality headset (control group).

Study Design

Study Type
Interventional
Allocation
Randomized
Intervention Model
Parallel
Primary Purpose
Treatment
Masking
None

Eligibility Criteria

Ages
18 Years to — (Adult, Older Adult)
Sex
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  • Shock wave lithotripsy and outpatient surgery

Exclusion Criteria

  • Deafness, Blindness
  • Schizophrenia, Hallucinations
  • No french-speaking
  • Motion sickness

Outcomes

Primary Outcomes

Remifentanil use

Time Frame: Hour 1

Remifentanil consumption (microgram) during shock wave lithotripsy

Secondary Outcomes

  • Maximal level of pain during shock wave lithotripsy(Hour 1)

Investigators

Sponsor Class
Other
Responsible Party
Sponsor

Study Sites (3)

Loading locations...

Similar Trials